Related Experiment Video
Updated: Mar 14, 2026
06:51
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
13.4K
Cefoperazone Induced Gastrointestinal Bleeding.
Goutham Reddy Katukuri1, Raja Naga Mahesh Maddala1, Kusugodlu Ramamoorthi2
1Junior Resident, Department of General Medicine, Kasturba Medical College, Kasturba Hospital , Manipal, Udupi, Karnataka, India .
Journal of Clinical and Diagnostic Research : JCDR
|September 23, 2016
Summary
Cefoperazone, an antibiotic, can cause bleeding by interfering with vitamin K metabolism. This case highlights a probable link between cefoperazone use and a patient
Area of Science:
- Pharmacology
- Internal Medicine
- Hematology
Background:
- Cefoperazone is a broad-spectrum beta-lactam antibiotic.
- It is widely prescribed for gram-positive and gram-negative bacterial infections.
Observation:
- A patient developed gastrointestinal bleeding.
- The bleeding was associated with cefoperazone administration.
Findings:
- The N-methylthiotetrazole side chain of cefoperazone can inhibit vitamin K metabolism.
- This inhibition leads to hypoprothrombinemia, a condition of reduced prothrombin in the blood.
- A Naranjo assessment score of 5 indicated a probable causal relationship between cefoperazone and the observed coagulopathy.
Implications:
- Cefoperazone-induced coagulopathy is a potential adverse drug event.
- Clinicians should monitor coagulation function in patients receiving cefoperazone.
- Awareness of this side effect is crucial for patient safety and effective treatment.
Related Concept Videos
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
1.3K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.3K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
591
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
591
01:29Inflammatory Bowel Disease IV: Pharmacological Management
893
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
893
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.9K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.9K
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
595
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
595
01:21Drugs for Treatment of Constipation-Predominant IBS
1.1K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.1K